Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Prospective, Single-center, Randomized, Controlled Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma

NCT04367909 is registered in ClinicalTrials.gov with Xin-Hua Xu as lead sponsor.

NCT NCT04367909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04367909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Prospective, Single-center, Randomized, Controlled Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma
Lead sponsor
Xin-Hua Xu
Phase
Phase 2
Overall status
Unknown status
Start date
June 21, 2020
Completion date
December 1, 2022
Enrollment
68 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

oral squamous cell carcinoma